Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more) Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Abbvie Inc ABBV

Alternate Symbol(s):  N.ABBV

Healthcare Biotechnology
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, and more. The Company, through Mitokinin, Inc., offers a lead compound, PINK1 activator, designed to address mitochondrial dysfunction.


NYSE:ABBV - Post by User

Abbvie Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
  • NonyahX
Post by Nonyahon Aug 09, 2020 10:42am
130 Views
Post# 31384329

Dev Tools

Dev Tools

Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
<< Previous
 Bullboard Posts
Next >>